Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: B.D. who wrote (27782)	2/3/1999 10:11:00 AM
From: Monte High	Read Replies (1) \| Respond to of 32384

Acute promyelocytic leukemia-Panretin works as well as ATRA

To: B.D. who wrote (27782)	2/3/1999 10:44:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Panretin oral is in several advanced trials including Kaposi Sarcoma, Acute Promyelocytic Leukemia, and psoriasis (I believe that the psoriasis Phase II trial has been completed). For the gel, LGND has talked about squamous cell carcinomas, but to my knowledge, such trials have not begun. Applications for non-malignant conditions such as acne, psoriasis, and wrinkles are easy to envision, because Pantein's (9-cis retinoic acid) molecular cousins, Tretinoin (all-trans retinoic acid) and isotretinoin (13-cis retinoic acid) are the active ingredients in approved topical treatments such as Retin-A, Renova, and Accutane. However, to my knowledge, LGND has not begun clinical treatments in these areas.